News

Pierre Fabre; Atara: CHMP Recommends Approval of Atara Biotherapeutics’ EbvalloTM (tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

Atara Biotherapeutics, Inc. and Pierre Fabre today announced the CHMP of the EMA has adopted a positive opinion recommending the EC approval of EbvalloTM (tabelecleucel) as a monotherapy for treatment of adult and pediatric patients two years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD), who have received at least one prior therapy.

Read more

Cherry Biotech – new member

Cherry Biotech is a world-class PharmaTech, French, helping pharma, biotech, and CRO in their preclinical 3D vascularized immuno-competent organoids.

Read more

This is a unique website which will require a more modern browser to work!

Please upgrade today!